BLACK DIAMOND THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BLACK DIAMOND THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $217.00K, a 734.62% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $121.00K, a 278.13% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $26.00K, a 93.32% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $32.00K, a 60.00% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $209.00K, a 73.81% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $798.00K, a 3890.00% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $20.00K, a 25.00% increase from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $16.00K, a 97.59% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $217.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $209.00K 10-K · filed 2026-03-16 | |
| 2025-09-30 | $121.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $26.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $798.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $32.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $389.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $86.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $20.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $20.00K 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $16.00K 10-K · filed 2024-03-12 | |
| 2022-09-30 | $5.00K 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $11.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $665.00K 10-K · filed 2023-03-09 | |
| 2021-06-30 | $184.00K 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $481.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $1.10M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $270.00K 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |